Myocarditis and pericarditis post-mRNA covid-19 vaccination: insights from a pharmacovigilance perspective

Abstract: Concerns remain regarding the rare cardiovascular adverse events, myocarditis and pericarditis (myo/pericarditis), particularly in younger individuals following mRNA COVID-19 vaccination. Our study aimed to comprehensively assess potential safety signals related to these cardiac events following the primary and booster doses, with a specific focus on younger populations, including children as young as 6 months of age. Using the Vaccine Adverse Events Reporting System (VAERS), the United States national passive surveillance system, we conducted a retrospective pharmacovigilance study analyzing spontaneous reports of myo/pericarditis. We employed both frequentist and Bayesian methods and conducted subgroup analyses by age, sex, and vaccine dose. We observed a higher reporting rate of myo/pericarditis following the primary vaccine series, particularly in males and mainly after the second dose. However, booster doses demonstrated a lower number of reported cases, with no significant signals detected after the fourth or fifth doses. In children and young adults, we observed notable age and sex differences in the reporting of myo/pericarditis cases. Males in the 12–17 and 18–24-year-old age groups had the highest number of cases, with significant signals for both males and females after the second dose. We also identified an increased reporting for a spectrum of cardiovascular symptoms such as chest pain and dyspnea, which increased with age, and were reported more frequently than myo/pericarditis. The present study identified signals of myo/pericarditis and related cardiovascular symptoms after mRNA COVID-19 vaccination, especially among children and adolescents. These findings underline the importance for continued vaccine surveillance and the need for further studies to confirm these results and to determine their clinical implications in public health decision-making, especially for younger populations.

Saved in:
Bibliographic Details
Main Authors: Alami, Abdallah, Villeneuve, Paul J., Farrell, Patrick J., Mattison, Donald, Farhat, Nawal, Haddad, Nisrine, Wilson, Kumanan, Gravel, Christopher A., Crispo, James A. G., Pérez Lloret, Santiago, Krewski, Daniel
Format: Artículo biblioteca
Language:eng
Published: MDPI 2023
Subjects:MIOCARDITIS, PERICARDITIS, FARMACOVIGILANCIA, COVID-19, VACUNACION,
Online Access:https://repositorio.uca.edu.ar/handle/123456789/17345
Tags: Add Tag
No Tags, Be the first to tag this record!
id oai:ucacris:123456789-17345
record_format koha
spelling oai:ucacris:123456789-173452023-11-23T18:04:11Z Myocarditis and pericarditis post-mRNA covid-19 vaccination: insights from a pharmacovigilance perspective Alami, Abdallah Villeneuve, Paul J. Farrell, Patrick J. Mattison, Donald Farhat, Nawal Haddad, Nisrine Wilson, Kumanan Gravel, Christopher A. Crispo, James A. G. Pérez Lloret, Santiago Krewski, Daniel MIOCARDITIS PERICARDITIS FARMACOVIGILANCIA COVID-19 VACUNACION Abstract: Concerns remain regarding the rare cardiovascular adverse events, myocarditis and pericarditis (myo/pericarditis), particularly in younger individuals following mRNA COVID-19 vaccination. Our study aimed to comprehensively assess potential safety signals related to these cardiac events following the primary and booster doses, with a specific focus on younger populations, including children as young as 6 months of age. Using the Vaccine Adverse Events Reporting System (VAERS), the United States national passive surveillance system, we conducted a retrospective pharmacovigilance study analyzing spontaneous reports of myo/pericarditis. We employed both frequentist and Bayesian methods and conducted subgroup analyses by age, sex, and vaccine dose. We observed a higher reporting rate of myo/pericarditis following the primary vaccine series, particularly in males and mainly after the second dose. However, booster doses demonstrated a lower number of reported cases, with no significant signals detected after the fourth or fifth doses. In children and young adults, we observed notable age and sex differences in the reporting of myo/pericarditis cases. Males in the 12–17 and 18–24-year-old age groups had the highest number of cases, with significant signals for both males and females after the second dose. We also identified an increased reporting for a spectrum of cardiovascular symptoms such as chest pain and dyspnea, which increased with age, and were reported more frequently than myo/pericarditis. The present study identified signals of myo/pericarditis and related cardiovascular symptoms after mRNA COVID-19 vaccination, especially among children and adolescents. These findings underline the importance for continued vaccine surveillance and the need for further studies to confirm these results and to determine their clinical implications in public health decision-making, especially for younger populations. 2023-10-24T11:45:25Z 2023-10-24T11:45:25Z 2023 Artículo Alami, A. et al. Myocarditis and pericarditis post-mrna covid-19 vaccination: insights from a pharmacovigilance perspective [en línea]. Journal of Clinical Medicine. 2023, 12 (15), 4971. doi: 10.3390/jcm12154971. Disponible en: https://repositorio.uca.edu.ar/handle/123456789/17345 2077-0383 https://repositorio.uca.edu.ar/handle/123456789/17345 10.3390/jcm12154971 37568373 eng Acceso abierto http://creativecommons.org/licenses/by-nc-sa/4.0/ application/pdf MDPI Journal of Clinical Medicine. Vol.12, No.15, 4971, 2023
institution UCA
collection DSpace
country Argentina
countrycode AR
component Bibliográfico
access En linea
databasecode dig-uca
tag biblioteca
region America del Sur
libraryname Sistema de bibliotecas de la UCA
language eng
topic MIOCARDITIS
PERICARDITIS
FARMACOVIGILANCIA
COVID-19
VACUNACION
MIOCARDITIS
PERICARDITIS
FARMACOVIGILANCIA
COVID-19
VACUNACION
spellingShingle MIOCARDITIS
PERICARDITIS
FARMACOVIGILANCIA
COVID-19
VACUNACION
MIOCARDITIS
PERICARDITIS
FARMACOVIGILANCIA
COVID-19
VACUNACION
Alami, Abdallah
Villeneuve, Paul J.
Farrell, Patrick J.
Mattison, Donald
Farhat, Nawal
Haddad, Nisrine
Wilson, Kumanan
Gravel, Christopher A.
Crispo, James A. G.
Pérez Lloret, Santiago
Krewski, Daniel
Myocarditis and pericarditis post-mRNA covid-19 vaccination: insights from a pharmacovigilance perspective
description Abstract: Concerns remain regarding the rare cardiovascular adverse events, myocarditis and pericarditis (myo/pericarditis), particularly in younger individuals following mRNA COVID-19 vaccination. Our study aimed to comprehensively assess potential safety signals related to these cardiac events following the primary and booster doses, with a specific focus on younger populations, including children as young as 6 months of age. Using the Vaccine Adverse Events Reporting System (VAERS), the United States national passive surveillance system, we conducted a retrospective pharmacovigilance study analyzing spontaneous reports of myo/pericarditis. We employed both frequentist and Bayesian methods and conducted subgroup analyses by age, sex, and vaccine dose. We observed a higher reporting rate of myo/pericarditis following the primary vaccine series, particularly in males and mainly after the second dose. However, booster doses demonstrated a lower number of reported cases, with no significant signals detected after the fourth or fifth doses. In children and young adults, we observed notable age and sex differences in the reporting of myo/pericarditis cases. Males in the 12–17 and 18–24-year-old age groups had the highest number of cases, with significant signals for both males and females after the second dose. We also identified an increased reporting for a spectrum of cardiovascular symptoms such as chest pain and dyspnea, which increased with age, and were reported more frequently than myo/pericarditis. The present study identified signals of myo/pericarditis and related cardiovascular symptoms after mRNA COVID-19 vaccination, especially among children and adolescents. These findings underline the importance for continued vaccine surveillance and the need for further studies to confirm these results and to determine their clinical implications in public health decision-making, especially for younger populations.
format Artículo
topic_facet MIOCARDITIS
PERICARDITIS
FARMACOVIGILANCIA
COVID-19
VACUNACION
author Alami, Abdallah
Villeneuve, Paul J.
Farrell, Patrick J.
Mattison, Donald
Farhat, Nawal
Haddad, Nisrine
Wilson, Kumanan
Gravel, Christopher A.
Crispo, James A. G.
Pérez Lloret, Santiago
Krewski, Daniel
author_facet Alami, Abdallah
Villeneuve, Paul J.
Farrell, Patrick J.
Mattison, Donald
Farhat, Nawal
Haddad, Nisrine
Wilson, Kumanan
Gravel, Christopher A.
Crispo, James A. G.
Pérez Lloret, Santiago
Krewski, Daniel
author_sort Alami, Abdallah
title Myocarditis and pericarditis post-mRNA covid-19 vaccination: insights from a pharmacovigilance perspective
title_short Myocarditis and pericarditis post-mRNA covid-19 vaccination: insights from a pharmacovigilance perspective
title_full Myocarditis and pericarditis post-mRNA covid-19 vaccination: insights from a pharmacovigilance perspective
title_fullStr Myocarditis and pericarditis post-mRNA covid-19 vaccination: insights from a pharmacovigilance perspective
title_full_unstemmed Myocarditis and pericarditis post-mRNA covid-19 vaccination: insights from a pharmacovigilance perspective
title_sort myocarditis and pericarditis post-mrna covid-19 vaccination: insights from a pharmacovigilance perspective
publisher MDPI
publishDate 2023
url https://repositorio.uca.edu.ar/handle/123456789/17345
work_keys_str_mv AT alamiabdallah myocarditisandpericarditispostmrnacovid19vaccinationinsightsfromapharmacovigilanceperspective
AT villeneuvepaulj myocarditisandpericarditispostmrnacovid19vaccinationinsightsfromapharmacovigilanceperspective
AT farrellpatrickj myocarditisandpericarditispostmrnacovid19vaccinationinsightsfromapharmacovigilanceperspective
AT mattisondonald myocarditisandpericarditispostmrnacovid19vaccinationinsightsfromapharmacovigilanceperspective
AT farhatnawal myocarditisandpericarditispostmrnacovid19vaccinationinsightsfromapharmacovigilanceperspective
AT haddadnisrine myocarditisandpericarditispostmrnacovid19vaccinationinsightsfromapharmacovigilanceperspective
AT wilsonkumanan myocarditisandpericarditispostmrnacovid19vaccinationinsightsfromapharmacovigilanceperspective
AT gravelchristophera myocarditisandpericarditispostmrnacovid19vaccinationinsightsfromapharmacovigilanceperspective
AT crispojamesag myocarditisandpericarditispostmrnacovid19vaccinationinsightsfromapharmacovigilanceperspective
AT perezlloretsantiago myocarditisandpericarditispostmrnacovid19vaccinationinsightsfromapharmacovigilanceperspective
AT krewskidaniel myocarditisandpericarditispostmrnacovid19vaccinationinsightsfromapharmacovigilanceperspective
_version_ 1787224531292651520